By the way,
and BioSante have not disclosed the exact royalty rate on Libigel sales except to say that it's mid-single digits.
Bob H.'s email is more indicative of the response I've received about BioSante this week:
"Wow, you are a [bleep]ing [bleep]! Pretty clear you [bleep]ing some [bleep], you [bleep]ing [bleep]. Go [bleep] yourself -- nobody likes you."
I did post the uncensored and clearly NSFW version of Bob's email to my
for those who want a laugh.
@oncoslearning asks, "What's your take on
and the impact of their recent stock offering?"
The $65 million stock offering, priced at $5.50 per share, probably doesn't do much to enhance Exelixis' credibility with investors. Remember, the company raised money almost a year ago at $11 per share. Deal pricing is going in the wrong direction.
Stepping back from the stock offering, Exelixis' experimental prostate cancer drug cabozantinib -- "cabo" for short -- suffers from an identity crisis. Existing cabo data suggest the drug is effective at reducing bone pain in late-stage prostate cancer patients, yet FDA won't allow the drug to be approved based solely on a pain-lowering benefit. Exelixis must show that cabo can prolong survival but where is the evidence the drug can do that?
Further clouding cabo's future are competing drugs -- Zytiga, MDV3100, Alpharadin, OGX-011-- that have demonstrated or may demonstrate a survival benefit in prostate cancer patients well before the two phase III studies of cabo are completed.
For Exelixis, cabo might be too little, too late.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
and become a fan on